ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 55c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q1 EPS of ($0.62), $0.55 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $44.21 million versus the consensus estimate of $43.07 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
• Meta Platforms (META) spreader of March 900 and 1100 calls as share price up in last three weeks
• Ennis (EBF) Misses Q2 EPS by 2c